The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?
Christopher Hourigan of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, gives his press briefing on the late-breaking abstract of genomic evidence of residual disease in acute myeloid leukemia (AML) patients in remission prior to allogeneic stem cell transplant. He discusses whether this is fate or an opportunity for early intervention. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
